Eugene Jiang - 02 Aug 2021 Form 3 Insider Report for ABVC BIOPHARMA, INC. (ABVC)

Reporting relationship: Chairman of the Board & CBO, Director
Issuer ticker: ABVC
Reported as of: 02 Aug 2021
Net transaction value: $0
SEC form: 3
Accepted by SEC: 15 Nov 2021, 11:25:30 UTC
Source filing: View source filing
Reporting owner signature: /s/ Eugene Jiang

Key filing fact

Eugene Jiang filed Form 3 for ABVC BIOPHARMA, INC. (ABVC) on 15 Nov 2021.

Key facts

This page summarizes Eugene Jiang's Form 3 filing for ABVC BIOPHARMA, INC. (ABVC).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 15 Nov 2021, 11:25.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABVC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 732,716
Date: 02 Aug 2021
Ownership: See Footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Mr. Jiang holds 701,989 shares of the Company's common stock through his ownership in AsianGene, 5,352 shares of the Company's common stock through his ownership in BioFirst Corporation, 202 shares of the Company's common stock through his ownership in Rgene Corporation, and the rest of 25,173 shares through direct ownership. BioFirst and Rgene Corporation are related parties of the Company.